A Phase I, Open-label, Single Arm Study to Evaluate the Safety, Tolerability, and Antitumor Activity of BRY805 in Participants With Advanced Solid Tumors
Latest Information Update: 06 Mar 2024
At a glance
- Drugs BRY 805 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors BioRay Pharmaceutical
Most Recent Events
- 06 Mar 2024 New trial record